While testing can identify the presence of the mutated prion protein gene, doctors cannot yet cure the condition.
The story of John Camidge, who lost his mother, uncle, and sister to this hereditary condition, illustrates the profound impact of genetic inheritance within families. John discovered through clinical testing in 2005 that he did not carry the gene mutation associated with familial CJD, while his sister, Diana, later died from a form of the disease in 2016.
Creutzfeldt-Jakob disease is fundamentally a disorder of protein folding. The condition is driven by prions—misfolded, infectious proteins that act as a template, forcing normal cellular proteins in the brain to adopt the same abnormal, pathological shape. This leads to the rapid, irreversible destruction of neural tissue, manifesting in the profound cognitive and motor decline seen in patients.
While the most widely recognized form is variant CJD—linked to the consumption of beef infected with bovine spongiform encephalopathy (BSE)—familial CJD arises from an autosomal dominant mutation in the PRNP gene. This means that an individual with an affected parent has a 50 percent statistical probability of inheriting the genetic predisposition.
The diagnostic journey for families often involves navigating misattributions, as early symptoms of CJD can mimic other neurodegenerative conditions like Huntington’s disease. As John Camidge noted, the family initially suspected Huntington’s before specialized testing at a dedicated prion clinic confirmed the presence of the PRNP mutation. His sister Diana was eventually diagnosed with Gerstmann–Sträussler–Scheinker syndrome (GSS), a rare, inherited form of prion disease.
“I felt like I was watching an action replay of what happened to our mum; only so much quicker.” John Camidge said.
| CJD Classification | Primary Cause | Incidence/Probability |
|---|---|---|
| Sporadic | Spontaneous protein misfolding | Most cases |
| Familial | Inherited PRNP mutation | Rare cases |
| Variant | Ingestion of BSE-infected tissue | Extremely rare since 1996 |
Currently, there is no disease-modifying therapy for CJD. Clinical management is strictly palliative, focusing on the mitigation of seizures, physical discomfort, and cognitive distress. Research into therapeutic candidates, such as the experimental drug PRN100, continues to be explored in clinical trials to assess potential efficacy in slowing the rapid progression of the disease.
Genetic testing for the PRNP mutation carries heavy psychosocial consequences and should only be undertaken after extensive counseling.
“I couldn't bear for Diana to spend her days knowing the odds had turned against her.” John Camidge said.
Clinical intervention is warranted if an individual begins to exhibit rapid-onset cognitive decline, unexplained loss of coordination (ataxia), visual disturbances, or sudden changes in personality. Because CJD progresses quickly—often resulting in mortality within 12 months of symptom onset—early neurological assessment is critical to rule out treatable neurological conditions that may present with similar symptoms, such as autoimmune encephalitis or metabolic disorders.
“If we can find a cure, I’ll go to my grave a happy man knowing we’ve spared other families the grief that’s surrounded mine,” John Camidge told The Irish Sun regarding his ongoing efforts to support research.
